{"id":"W2024644107","doi":"10.1002/art.22025","title":"Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks","year":2006,"lang":"en","type":"article","venue":"Arthritis & Rheumatism","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":1640,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"National Center for Research Resources","keywords":"Medicine; Rituximab; Rheumatoid arthritis; Internal medicine; Placebo; Rheumatology; Rheumatism; Randomized controlled trial; Clinical endpoint; Population; Surgery; Physical therapy; Lymphoma; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0311017115630682,"score_gpt":0.3213398643868879,"score_spread":0.2902381528238197,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}